Other human studies in non-alcoholic fatty liver disease (NAFLD) have provided evidence that GDF15 levels are significantly associated with advanced fibrosis and could also be potentially involved in linking type 2 diabetes and fibrosis in NAFLD [13,36]. Here, GDF15 is linked to metabolic dysfunction-associated steatotic liver disease.